These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 36845125)

  • 1. Platforms, advances, and technical challenges in virus-like particles-based vaccines.
    Gupta R; Arora K; Roy SS; Joseph A; Rastogi R; Arora NM; Kundu PK
    Front Immunol; 2023; 14():1123805. PubMed ID: 36845125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-like particles in vaccine development.
    Roldão A; Mellado MC; Castilho LR; Carrondo MJ; Alves PM
    Expert Rev Vaccines; 2010 Oct; 9(10):1149-76. PubMed ID: 20923267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plant-derived virus-like particles as vaccines.
    Chen Q; Lai H
    Hum Vaccin Immunother; 2013 Jan; 9(1):26-49. PubMed ID: 22995837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.
    Kushnir N; Streatfield SJ; Yusibov V
    Vaccine; 2012 Dec; 31(1):58-83. PubMed ID: 23142589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like Particle Vaccines and Platforms for Vaccine Development.
    Kheirvari M; Liu H; Tumban E
    Viruses; 2023 May; 15(5):. PubMed ID: 37243195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and future directions of fish vaccines employing virus-like particles.
    Jeong KH; Kim HJ; Kim HJ
    Fish Shellfish Immunol; 2020 May; 100():49-57. PubMed ID: 32130976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a yeast-based VLP platform for antigen presentation.
    Wetzel D; Rolf T; Suckow M; Kranz A; Barbian A; Chan JA; Leitsch J; Weniger M; Jenzelewski V; Kouskousis B; Palmer C; Beeson JG; Schembecker G; Merz J; Piontek M
    Microb Cell Fact; 2018 Feb; 17(1):17. PubMed ID: 29402276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particles as powerful vaccination strategy against human viruses.
    Hadj Hassine I; Ben M'hadheb M; Almalki MA; Gharbi J
    Rev Med Virol; 2024 Jan; 34(1):e2498. PubMed ID: 38116958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of virus-like particle vaccines against respiratory viruses.
    Quan FS; Basak S; Chu KB; Kim SS; Kang SM
    Expert Rev Vaccines; 2020 Jan; 19(1):11-24. PubMed ID: 31903811
    [No Abstract]   [Full Text] [Related]  

  • 12. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines.
    Thompson D; Metz SW; Abad C; Beaty S; Warfield K
    Vaccine; 2022 May; 40(22):3009-3017. PubMed ID: 35459557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic.
    López-Macías C
    Hum Vaccin Immunother; 2012 Mar; 8(3):411-4. PubMed ID: 22330956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.
    Chu KB; Quan FS
    Curr Top Microbiol Immunol; 2021; 433():77-106. PubMed ID: 33650036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity chromatography for virus-like particle manufacturing: Challenges, solutions, and perspectives.
    Ma J; Tian Z; Shi Q; Dong X; Sun Y
    J Chromatogr A; 2024 Apr; 1721():464851. PubMed ID: 38574547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particles for the prevention of human papillomavirus-associated malignancies.
    Wang JW; Roden RB
    Expert Rev Vaccines; 2013 Feb; 12(2):129-41. PubMed ID: 23414405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.